While all men are at risk for prostate cancer, there are disproportionate gaps in treatment, research, clinical trials and mortality rates among African American men that need to be recognized and can be addressed with the aid of AI
Related Articles
ArteraAI Achieves SOC 2 Type II Security Compliance Certification
ArteraAI x SOC 2 As part of our commitment to cybersecurity, we are proud to announce that ArteraAI is now SOC 2 Type II cert [...]
ArteraAI Predictive Models
ArteraAI is a leading precision medicine company developing AI tests to personalize cancer therapy. Download the pdf.